Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levofloxacin + clindamycin is a combination of two antibiotics used together to treat infections caused by susceptible bacteria, particularly when both aerobic and anaerobic coverage is needed. Levofloxacin is a fluoroquinolone antibiotic that acts by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby blocking DNA replication and leading to bacterial cell death. Clindamycin is a lincosamide antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit of susceptible bacteria, primarily affecting anaerobic bacteria and some gram-positive organisms. The combination may be used in clinical scenarios where mixed infections are suspected or confirmed, such as intra-abdominal or soft tissue infections. Studies have shown synergistic effects against certain anaerobes when these drugs are combined[1][3]. Both agents should be prescribed with caution due to their individual side effect profiles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levofloxacin + clindamycin.